Skip to main content

Table 2 SBRT parameters, outcomes, and adverse events (n = 16)

From: Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series

SBRT treatment, median (range)  
SBRT dose, Gy 45.0 (28–60)
Number of fractions 5 (4–5)
EQD2, Gy 71.25 (36.4–110.0)
Tumor volume, cc 35.9 (1.11–819.43)
Number of targeted lesions 2 (1–4)
Normal liver volume, cc 1281.7 (537.0–2095.1)
rV15* of uninvolved liver, cc 1019.6 (436.6–1610.2)
SBRT outcomes, no. (%)  
Radiographic response  
 Complete response (rCR) 4 (25)
 Partial response (rPR) 6 (37.5)
 Stable disease (rSD) 6 (37.5)
Local recurrence  
 Out-field 11 (68.8)
 In-field 0
AFP after SBRT**, median (range), IU/mL 38.3 (2.8–386.3)
Within Millan criteria after SBRT 5 of 14 patients (35.7)
Adverse events, no. (%) Grade 1 Grade 2 Grade3 Grade4
Biochemical     
 Albumin 3 (18.8) 3 (18.8) 0 0
 Alkaline phosphatase 1 (6.3) 0 0 0
 ALT 7 (43.8) 0 0 0
 AST 7 (43.8) 0 0 0
 Bilirubin 0 1 (6.3) 1 (6.3) 1 (6.3)
Hematologic     
 Anemia 3 (18.8) 1 (6.3) 1 (6.3) 0
 Leukocytopenia 6 (37.5) 1 (6.3) 1 (6.3) 0
 Thrombocytopenia 5 (31.3) 1 (6.3) 3 (18.8) 0
 Fatigue 2 (12.5) 0 0 0
Gastrointestinal toxicity     
 Abdominal pain 2 (12.5) 0 0 0
 Anorexia 1 (6.3) 0 0 0
 Diarrhea 1 (6.3) 1 (6.3) 0 0
 Nausea/vomiting 1 (6.3) 2 (12.5) 0 0
RILD, no. (%)  
 Classic 0 (0)
 Nonclassic 1 (6.3)
  1. AST, aspartate aminotransferase; ALT, alanine aminotransferase; rCR, radiological complete response; rPR, radiological partial response; rSD, radiological stable disease; RILD, radiation induced liver disease; SBRT, stereotactic body radiation therapy
  2. *rV15 was defined as volume of uninvolved liver receiving ≤ 15 Gy (cc)
  3. **Only apply for patients with elevated AFP level at baseline